SecBot SecBot
DEF 14A ·Filed Nov 12, 2026

SBFM

Sunshine Biopharma Inc.
BEARISH
Impact 5/10
Horizonweeks Processed9d 16h ago SEC0001683168-26-008615
Definitive proxy statement
Actionable Insight ▼ Bearish

The 7M share plan increase is virtually certain to pass given CEO voting control. Monitor the pace of equity grants post-approval and any associated S-8 filings. The company's cash burn rate and need for capital suggest further dilutive financing is likely.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.70
T+0 close · Nov 12, 2026 · via day close
Latest settled
−17.41%
T+5 · $2.23
Vs SPY
−8.85%
α at T+5
Next horizon
T+20
in 22d
  1. T+0 · Nov 13 $2.70entry
  2. T+1 · 6d ago −3.70%α −1.79% · $2.60
  3. T+5 · 2d ago −17.41%α −8.85% · $2.23
  4. T+20 · in 22d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sunshine Biopharma's 2026 proxy statement seeks shareholder approval to increase the 2023 Equity Incentive Plan share reserve from 3,415 to 7,000,000 shares, a massive 2,050x increase. The company has no shares remaining under the plan, and the CEO holds 130,000 Series B Preferred shares with 1,000 votes each, giving him effective control over all voting matters. The company has sustained net losses of $5.98M in 2025, $5.13M in 2024, and $4.51M in 2023, with zero total shareholder return over three years.

Key Facts

  • Proposal to increase 2023 Equity Incentive Plan shares from 3,415 to 7,000,000 shares (a 2,050x increase)
  • CEO Dr. Steve Slilaty holds 130,000 Series B Preferred shares with 1,000 votes each, giving him 130 million votes vs. 823,772 common shares outstanding
  • No shares currently available under the 2023 Plan; all 3,415 previously authorized shares were issued to one director in 2026
  • Net losses: ($5,975,352) in 2025, ($5,134,116) in 2024, ($4,506,044) in 2023
  • Total shareholder return of $0 on a $100 investment over three years (three reverse stock splits totaling ~400,000-fold reduction)
  • CEO 2025 total compensation: $465,953; CEO severance upon termination without cause: $14 million
  • Three 5%+ holders: Intracoastal Capital (9.99%), CVI Investments (9.3%), BJI Financial Group (5.6%)
  • Auditor changed from Bush & Associates to M&K CPAS in September 2025

Financial Impact

Proposed 7,000,000 share increase represents 850% dilution relative to 823,772 common shares outstanding; CEO controls 130 million votes via Series B Preferred, ensuring passage

dilutionshare countnet income

Risk Factors

  • Massive potential dilution of 850% from the equity plan increase
  • CEO has unilateral voting control over all proposals via Series B Preferred stock
  • Sustained net losses with no path to profitability disclosed
  • Three reverse stock splits in three years indicate Nasdaq compliance challenges
  • CEO's $14 million severance clause creates a significant contingent liability

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001683168-26-008615
Document: 0001683168-26-008615-index-headers.html0001683168-26-008615
Document: 0001683168-26-008615-index.html0001683168-26-008615
Document: 0001683168-26-008615.txt0001683168-26-008615

Track record

15 reports on SBFM

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +69.19% at T+20 after the Oct 8, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 18, 20263d ago S-1 Bearish 6/10 Entry $2.35 Now $2.23 +5.11% settles Nov 27
  2. Nov 13, 20268d ago DEFA14A Bearish 5/10 Entry $2.60 Now $2.23 +14.23% settles Nov 23
  3. Nov 12, 20269d ago DEF 14A Bearish 5/10 Viewing Entry $2.70 to $2.23 Now $2.23 +17.41% ▲ +17.41% +8.85% vs SPY
  4. Nov 10, 202611d ago SC 13G/A Neutral 2/10 Entry $2.75 to $2.41 Now $2.23 −18.91% ▼ −12.36% −8.47% vs SPY
  5. Oct 14, 20265w ago SC 13G Neutral 3/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
  6. Oct 13, 20265w ago SC 13G Neutral 4/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
  7. Oct 9, 20266w ago 8-K Bearish 6/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
  8. Oct 9, 20266w ago 424B4 Bearish 7/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
  9. Oct 8, 20266w ago EFFECT Bearish 6/10 Entry $8.60 to $4.60 Now $2.23 +74.07% ▲ +46.51% +46.24% vs SPY
  10. Oct 5, 20266w ago SC 13G/A Bearish 5/10 Entry $0.3979 to $0.2363 Now $2.23 −460.44% ▲ +40.61% +40.47% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Mon (25h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026